Skip to content

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

Multicenter phase. trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q2Scopus Q4
Journal
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY10(12) · pp.505 · 2018
Citation
Web of Science 24Scopus 26
FWCI (Scopus)
1.19
JCR IF
JCR 2017 3.14
ISSN
1948-5204

Authors

  1. Chung, Moon JaeFirst authorDivision of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
  2. Kang, HuapyongDivision of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
  3. Kim, Ho GakDepartment of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, South Korea
  4. Hyun, Jong JinDepartment of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, South Korea
  5. Lee, Jun KyuDepartment of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, South Korea
  6. Lee, Kwang HyuckDivision of Gastroenterology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  7. Noh, Myung HwanDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea
  8. Kang, Dae-hwanDepartment of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine, Pusan National University Yangsan Hospital, Research Institute for Convergence of Biomedical Science and Technology, Yangsan, South Korea
  9. Lee, Sang HyubDepartments of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
  10. Bang, SeungminCorresponding authorDivision of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Abstract

AIM To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS This study was a prospective, multicenter, one-arm, open-label, phase. trial. Patients with unresectable PC, who showed disease progression during GEM-based chemotherapy were enrolled. All patients were administered FOLFIRINOX with reduced irinotecan and oxaliplatin (RIO; irinotecan 120 mg/m(2) and oxaliplatin 60 mg/m(2)), which was set according to the phase. study of FOLFIRINOX. The objective response rate (ORR), disease control rate (DCR), progressionfree survival (PFS), overall survival (OS), adverse events were evaluated. Additionally, changes in quality of life (QoL) were assessed using a questionnaire on QoL. RESULTS Between August 2015 and May 2016, a total of 48 patients were enrolled. The median follow-up time was 259 d with a median of 8.5 cycles. The ORR and DCR were 18.8% and 62.5%, respectively, including one patient who showed complete remission. The median PFS was 5.8 mo [ 95% confidence interval (CI): 3.7-7.9] and median OS was 9.0 mo (95% CI: 6.4-11.6). Neutropenia (64.6%) was the most common grade 3-4 adverse event, followed by febrile neutropenia (16.7%). Although 14.6% of patients experienced grade 3 fatigue, most non-hematologic AEs were under grade 2. In the QoL analysis, the global health status score before treatment was not different from the score at the last visit after treatment (45.43 +/- 22.88 vs 48.66 +/- 24.14, P = 0.548). CONCLUSION FOLFIRINOX with RIO showed acceptable toxicity and promising efficacy for GEM-refractory unresectable PC. However, this treatment requires careful observation of treatment-related hematologic toxicities.

Keywords

Pancreatic cancerFOLFIRINOXClinical Trial , PhaseChemotherapyGemcitabine refractoryQUALITY-OF-LIFE2ND-LINE CHEMOTHERAPYOXALIPLATIN FOLFIRINOXFOLINIC ACIDIRINOTECANADENOCARCINOMA5-FLUOROURACILLEUCOVORINTHERAPYFLUOROURACIL

Identifiers

Scopus EID
2-s2.0-85059121005
WoS UID
000455916900005